vs
Side-by-side financial comparison of Alibaba Group Holding Ltd (BABA) and Cardinal Health (CAH). Click either name above to swap in a different company.
Cardinal Health is the larger business by last-quarter revenue ($65.6B vs $38.8B, roughly 1.7× Alibaba Group Holding Ltd). Alibaba Group Holding Ltd runs the higher net margin — 5.8% vs 0.7%, a 5.0% gap on every dollar of revenue.
Alibaba Group Holding Limited, branded as Alibaba, is a Chinese multinational technology company specializing in e-commerce, retail, Internet, and technology. Founded on 28 June 1999 in Hangzhou, Zhejiang, the company provides consumer-to-consumer (C2C), business-to-consumer (B2C), and business-to-business (B2B) sales services via Chinese and global marketplaces, as well as local consumer, digital media and entertainment, logistics, and cloud computing services. It owns and operates a diverse...
Cardinal Health, Inc. is an American multinational health care services company, and the 15th highest revenue generating company in the United States. Headquartered in Dublin, Ohio, the company specializes in the distribution of pharmaceuticals and medical products, serving more than 100,000 locations. The company also manufactures medical and surgical product, including gloves, surgical apparel, and fluid management products.
BABA vs CAH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $38.8B | $65.6B |
| Net Profit | $2.2B | $467.0M |
| Gross Margin | 40.2% | 3.7% |
| Operating Margin | 6.6% | 1.1% |
| Net Margin | 5.8% | 0.7% |
| Revenue YoY | — | 19.6% |
| Net Profit YoY | — | -7.7% |
| EPS (diluted) | $6.64 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.8B | $65.6B | ||
| Q3 25 | $34.2B | — | ||
| Q2 25 | $32.6B | $60.2B | ||
| Q1 25 | — | $54.9B | ||
| Q4 24 | $38.7B | $55.3B | ||
| Q3 24 | — | $52.3B | ||
| Q2 24 | — | $59.7B | ||
| Q1 24 | — | $54.9B |
| Q4 25 | $2.2B | $467.0M | ||
| Q3 25 | $2.9B | — | ||
| Q2 25 | $1.7B | $239.0M | ||
| Q1 25 | — | $506.0M | ||
| Q4 24 | $6.8B | $400.0M | ||
| Q3 24 | — | $416.0M | ||
| Q2 24 | — | $236.0M | ||
| Q1 24 | — | $258.0M |
| Q4 25 | 40.2% | 3.7% | ||
| Q3 25 | 39.2% | — | ||
| Q2 25 | 38.4% | 3.7% | ||
| Q1 25 | — | 3.9% | ||
| Q4 24 | 42.0% | 3.5% | ||
| Q3 24 | — | 3.6% | ||
| Q2 24 | — | 3.1% | ||
| Q1 24 | — | 3.5% |
| Q4 25 | 6.6% | 1.1% | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 12.0% | 0.7% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | 14.7% | 1.0% | ||
| Q3 24 | — | 1.1% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 0.7% |
| Q4 25 | 5.8% | 0.7% | ||
| Q3 25 | 8.5% | — | ||
| Q2 25 | 5.3% | 0.4% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | 17.5% | 0.7% | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.5% |
| Q4 25 | $6.64 | — | ||
| Q3 25 | $8.72 | — | ||
| Q2 25 | $5.20 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $20.40 | — | ||
| Q3 24 | — | $1.70 | ||
| Q2 24 | — | $0.86 | ||
| Q1 24 | — | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.3B | $2.8B |
| Total DebtLower is stronger | — | $8.3B |
| Stockholders' EquityBook value | $148.7B | $-2.9B |
| Total Assets | $268.6B | $58.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.3B | $2.8B | ||
| Q3 25 | $19.0B | — | ||
| Q2 25 | $20.0B | $3.9B | ||
| Q1 25 | — | $3.3B | ||
| Q4 24 | $22.3B | $3.8B | ||
| Q3 24 | — | $2.9B | ||
| Q2 24 | — | $5.3B | ||
| Q1 24 | — | $3.7B |
| Q4 25 | — | $8.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.1B | ||
| Q4 24 | — | $7.1B | ||
| Q3 24 | — | $4.2B | ||
| Q2 24 | — | $4.7B | ||
| Q1 24 | — | $4.7B |
| Q4 25 | $148.7B | $-2.9B | ||
| Q3 25 | $145.0B | — | ||
| Q2 25 | $139.2B | $-2.8B | ||
| Q1 25 | — | $-2.9B | ||
| Q4 24 | $137.2B | $-3.0B | ||
| Q3 24 | — | $-3.3B | ||
| Q2 24 | — | $-3.2B | ||
| Q1 24 | — | $-3.3B |
| Q4 25 | $268.6B | $58.1B | ||
| Q3 25 | $264.6B | — | ||
| Q2 25 | $248.6B | $53.1B | ||
| Q1 25 | — | $49.9B | ||
| Q4 24 | $254.1B | $47.0B | ||
| Q3 24 | — | $43.1B | ||
| Q2 24 | — | $45.1B | ||
| Q1 24 | — | $45.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.2B | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 2.31× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.2B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $3.8B | $1.5B | ||
| Q1 25 | — | $2.9B | ||
| Q4 24 | $9.7B | $-400.0M | ||
| Q3 24 | — | $-1.6B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $-49.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $-499.0M | ||
| Q3 24 | — | $-1.7B | ||
| Q2 24 | — | $1.9B | ||
| Q1 24 | — | $-161.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | -0.9% | ||
| Q3 24 | — | -3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | -0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | 2.31× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 2.19× | 6.39× | ||
| Q1 25 | — | 5.76× | ||
| Q4 24 | 1.43× | -1.00× | ||
| Q3 24 | — | -3.96× | ||
| Q2 24 | — | 8.80× | ||
| Q1 24 | — | -0.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BABA
| Alibaba China E-commerce Group | $22.8B | 59% |
| All others | $9.6B | 25% |
| Cloud Intelligence Group | $6.2B | 16% |
CAH
| Pharmaceutical And Specialty Solutions | $60.7B | 92% |
| GMPD | $3.3B | 5% |
| At Home Solutions | $1.2B | 2% |
| Nuclear Precision Health Solutions | $440.0M | 1% |
| Opti Freight Logistics | $99.0M | 0% |
